Abstract
/l) were prospectively studied. Pa-tients with immune thrombocytopenia [7] , overt viral hepatitis or liver cirrhosis were excluded. The study was approved by the Ethics Committee of the Clinica Ruiz and informed consent was obtained from the patients in-cluded in both groups. Alpha 2 macroglobulin, haptoglo-bin, apolipoprotein A, bilirubin, gamma-glutamyl trans-peptidase, alanine aminotransferase, aspartate amino-transferase, glucose, cholesterol and triglycerides were measured in all patients. These biochemical markers were then analyzed. FibroTest was used for the quantitative as-sessment of fibrosis, SteatoTest for the quantitative as-sessment of steatosis, ActiTest for the quantitative assess-ment of necroinflammatory activity in chronic viral hep-atitis and NashTest for the categorical diagnosis of nonalcoholic steatohepatitis [5] . Patients with a score of >50% in either the SteatoTest or the NashTest coupled with a score of <50% in the FibroTest were defined as hav-ing NAFLD. Within the group of 93 consecutive patients studied due to their platelet count <100 × 10
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
